Autres langues Vaxart, Inc.

Actions

VXRT

US92243A2006

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
0,9446 ^USD	+9,24 %		+29,40 %	+64,91 %

13/05	Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
13/05	Vaxart, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Earnings Flash (VXRT) VAXART Reports Q1 Revenue $2.2M, vs. Street Est of $0.8M	13/05
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results	13/05
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13	07/05
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers	30/04
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3	27/03
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/03
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results	14/03
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14	07/03
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall	06/03
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director	06/03
Vaxart, Inc. Announces Chief Executive Officer Changes	06/03
Vaxart, Inc. Announces Management Appointments	06/03
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge	05/02
North American Morning Briefing : Stock Futures -2-	01/02
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	19/01
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	19/01
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise	16/01
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management	16/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vaxart, Inc.

Actions

VXRT

US92243A2006

Autres langues

Filtres